HORMONE REPLACEMENT THERAPY MARKET ANALYSIS

Hormone Replacement Therapy Market, By Therapy Type (Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, Testosterone Replacement Therapy, and Others), By Route of Administration (Oral, Parenteral, and Others), By Application (Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : May 2024
Code : CMI2079
Pages :151
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Hormone Replacement Therapy Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Increasing Prevalence of Various Chronic Conditions

Increasing prevalence of chronic conditions such as hypogonadism in adult men worldwide is expected to drive growth of the hormone replacement therapy market. For instance, in June 2021, according to the European Association of Urology, male hypogonadism is a disorder associated with decreased functional activity of the testes, with decreased production and/or action of androgens and/or impaired sperm production. This is caused by poor testicular function or as a result of inadequate stimulation of the testes by the hypothalamic-pituitary-gonadal (HPG) axis. Likewise, several congenital or acquired disorders causing impaired action of androgens have also been described. In men aged between 40 and 79 years old, the incidence of symptomatic hypogonadism varies between 2.1% and 5.7%. The incidence of hypogonadism has been reported to be 12.3 and 11.7 cases per 1,000 people per year in the U.S. Testosterone production declines as a function of age, and the prevalence of hypogonadism increases with aging.

Key Players Insights